ERX-11

ERX-11 is a BRCA1 inhibitor that is currently under investigation for its potential use in the treatment of cancer. It was developed by Elixirgen Therapeutics, a biopharmaceutical company based in Baltimore, Maryland, USA.

Mechanism of Action

ERX-11 works by inhibiting the function of the BRCA1 protein. BRCA1 is a tumor suppressor protein that plays a key role in repairing damaged DNA. In normal cells, BRCA1 helps to repair DNA damage, which prevents the development of tumors. However, in some cancer cells, BRCA1 is overactive, which allows these cells to repair their DNA and continue to grow and divide. By inhibiting BRCA1, ERX-11 prevents cancer cells from repairing their DNA, which leads to cell death.

Clinical Trials

ERX-11 is currently in the early stages of clinical development. Preclinical studies have shown that it is effective in killing cancer cells in the laboratory. Clinical trials are now underway to determine its safety and efficacy in humans.

Potential Applications

If successful in clinical trials, ERX-11 could be used to treat a variety of cancers, including breast cancer, ovarian cancer, and prostate cancer. It could be particularly useful in treating cancers that are resistant to other forms of treatment.

See Also

• BRCA1
• Cancer
• Breast cancer
• Ovarian cancer
• Prostate cancer

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

References

<references />

External Links

• Elixirgen Therapeutics

Further Reading

• "ERX-11 is an orally bioavailable, specific inhibitor of the BRCA1 DNA repair complex" (PubMed)
• "ERX-11" (National Cancer Institute Drug Dictionary)